Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Miceli

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
ESMO Open|March 13, 2021
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers NetworkA M Frezza, A Napolitano, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2011
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation studyR Granata, R Miceli, E Orlandi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 5, 2014
Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study)S Bauer, P Rutkowski, P Hohenberger, et al.
Leukemia|March 26, 2014
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphomaP Corradini, U Vitolo, A Rambaldi, et al.
ESMO Open|June 4, 2023
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical OncologyA G Leone, R Miceli, D Trapani, et al.
The Pharmacogenomics Journal|March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumabF S Falvella, C Cremolini, R Miceli, et al.
Expert Review of Clinical Pharmacology|January 21, 2021
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trialA Mennitto, E Verzoni, F Cognetti, et al.
Leukemia|June 29, 2007
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcomeP Corradini, A Dodero, L Farina, et al.
Journal of Cancer Research and Clinical Oncology|January 17, 2022
Mammographic density to predict response to neoadjuvant systemic breast cancer therapyS Di Cosimo, C Depretto, R Miceli, et al.
Leukemia|January 12, 2019
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphomaA Dodero, A Guidetti, A Tucci, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
ESMO Open|March 13, 2021
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers NetworkA M Frezza, A Napolitano, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2011
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation studyR Granata, R Miceli, E Orlandi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 5, 2014
Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study)S Bauer, P Rutkowski, P Hohenberger, et al.
Leukemia|March 26, 2014
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphomaP Corradini, U Vitolo, A Rambaldi, et al.
ESMO Open|June 4, 2023
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical OncologyA G Leone, R Miceli, D Trapani, et al.
The Pharmacogenomics Journal|March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumabF S Falvella, C Cremolini, R Miceli, et al.
Expert Review of Clinical Pharmacology|January 21, 2021
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trialA Mennitto, E Verzoni, F Cognetti, et al.
Leukemia|June 29, 2007
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcomeP Corradini, A Dodero, L Farina, et al.
Journal of Cancer Research and Clinical Oncology|January 17, 2022
Mammographic density to predict response to neoadjuvant systemic breast cancer therapyS Di Cosimo, C Depretto, R Miceli, et al.
Leukemia|January 12, 2019
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphomaA Dodero, A Guidetti, A Tucci, et al.
Pageof 10